Based on the Vericel Corp Ord stock forecast from 6 analysts, the average analyst target price for Vericel Corp Ord is USD 57.75 over the next 12 months. Vericel Corp Ord’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Vericel Corp Ord is Slightly Bullish , which is based on 9 positive signals and 5 negative signals. At the last closing, Vericel Corp Ord’s stock price was USD 55.47. Vericel Corp Ord’s stock price has changed by +15.47% over the past week, +33.05% over the past month and +50.94% over the last year.
No recent analyst target price found for Vericel Corp Ord
No recent average analyst rating found for Vericel Corp Ord
Company Overview Vericel Corp Ord
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts. Read Less
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products com...Read More
Frequently Asked Questions About Vericel Corp Ord (VCEL) Stock
Based on ratings from 6 analysts Vericel Corp Ord's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 8 buy, sell and hold ratings.
Unfortunately we do not have enough data on VCEL's stock to indicate if its a good dividend stock.
Based on targets from 6 analysts, the average taret price for VCEL is USD 57.75 over the next 12 months. The maximum analyst target price is USD 60 while the minimum anlayst target price is USD 55.
VCEL stock's Price/Earning ratio is 675.00.
Our analysis grades VCEL stock's Price / Earning ratio at F. This means that VCEL stock's Price/Earning ratio is above 98% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this VCEL may be a overvalued for its sector.
The last closing price of VCEL's stock was USD 55.47.
The most recent market capitalization for VCEL is USD 2.67B.
Based on targets from 6 analysts, the average taret price for VCEL is projected at USD 57.75 over the next 12 months.
This means that VCEL's stock price may go up by +4.11% over the next 12 months.
We can't find any ETFs which contains Vericel Corp Ord's stock.
As per our most recent records Vericel Corp Ord has 314 Employees.
Vericel Corp Ord's registered address is 64 Sidney Street, Cambridge, MA, United States, 02139.
You can get more information about it from Vericel Corp Ord's website at https://vcel.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Vericel Corp Ord (VCEL) Stock
Based on ratings from 6 analysts Vericel Corp Ord's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 8 buy, sell and hold ratings.
Unfortunately we do not have enough data on VCEL's stock to indicate if its a good dividend stock.
Based on targets from 6 analysts, the average taret price for VCEL is USD 57.75 over the next 12 months. The maximum analyst target price is USD 60 while the minimum anlayst target price is USD 55.
VCEL stock's Price/Earning ratio is 675.00.
Our analysis grades VCEL stock's Price / Earning ratio at F. This means that VCEL stock's Price/Earning ratio is above 98% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this VCEL may be a overvalued for its sector.
The last closing price of VCEL's stock was USD 55.47.
The most recent market capitalization for VCEL is USD 2.67B.
Based on targets from 6 analysts, the average taret price for VCEL is projected at USD 57.75 over the next 12 months.
This means that VCEL's stock price may go up by +4.11% over the next 12 months.
We can't find any ETFs which contains Vericel Corp Ord's stock.
As per our most recent records Vericel Corp Ord has 314 Employees.
Vericel Corp Ord's registered address is 64 Sidney Street, Cambridge, MA, United States, 02139.
You can get more information about it from Vericel Corp Ord's website at https://vcel.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for VCEL !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
